Description
This is an engineered T7 RNA polymerase variant (low dsRNA) derived from the wild-type T7 RNA polymerase and produced in Escherichia coli. It significantly reduces the production of double-stranded RNA (dsRNA) while efficiently incorporating cap analogs, and exhibiting highly efficient in vitro transcription (IVT) comparable to the wild-type T7 RNA polymerase. It catalyzes the 5'→3' synthesis of RNA on double-stranded DNA from its T7 promoter sequence (5'-TAATACGACTCACTATAG*-3') and uses NTPs as substrates.
Note: G* is the first base of the RNA transcript.
Feature
- dsRNA level lower to about 1/100000
- Comptiable with Trilink CleanCap AG, LZCap
- High yields comparable to WT
- Lower Cap input
- Animal origin-free (AOF)
Please find information on the development of this enzyme.
Components
Components No. |
Name |
10629ES10 |
10629ES60 |
10629ES72 |
10629ES86 |
|
|
(10 KU) |
(100 KU) |
(250 KU) |
(2,500 KU) |
10629 |
CleaScrip™ T7 RNA Polymerase (GMP Grrade, low dsRNA, 250 U/μL) |
40 μL |
400 μL |
1 mL |
10 mL |
Specifications
Source |
Recombinant E. coli with T7 RNA Polymerase gene |
Optimum Temperature |
37℃ |
Storage Buffer |
50 mM Tris-HCl, 1 mM EDTA, 10 mM DTT, 100 mM NaCl, 0.1% Triton X-100,50% (v/v) glycerin,pH7.9 at 25℃ |
Unit Definition |
The amount of enzyme required to incorporate 1 nmol of [3H] GMP into the acid-insoluble precipitate within 1 hour at 37°C and pH 8.0 is defined as 1 unit. |
Recommended Mg2+ |
30mM Magnesium Acetate |
QC Standard
Items |
Specification/Standard |
Enzyme activity |
250-300U/μL |
Protein Purity |
≥95% |
Endotoxin |
<20 EU/mg |
Protease |
Negative |
Exonuclease |
Negative |
Nickase |
Negative |
RNase |
Negative |
E.coli host protein |
<50ppm |
E.coli host DNA |
<10 fg/U |
Mycoplasma examination |
Negative |
Related Products
Tris NTPs synergistically decreasing dsRNA
Figures

Figure 2. Evaluation of the immunogenicity of the IVT products in murine RAW264.7 cells (Figures 2A and 2B). IFN-β mRNA and protein levels were reduced in RAW264.7 cells transfected with mRNA produced by mutants compared to wild-type, indicating that mRNA synthesized by the wild-type T7 RNAP elicited the strongest immune response, while mRNA from the mutants showed a significantly reduced response.
Figure 3. The dsRNA content in mRNA synthesized with CleaScript™ T7 RNA polymerase is lower than that in mRNA synthesized with the wild-type enzyme after cellulose treatment.
Shipping and Storage
The products are shipped with dry ice and can be stored at -15℃ ~ -25℃ for one year.
Publication:
Documents
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.
Inquiry
You may also like
FAQ
The product is for research purposes only and is not intended for therapeutic or diagnostic use in humans or animals. Products and content are protected by patents, trademarks, and copyrights owned by Yeasen Biotechnology. Trademark symbols indicate the country of origin, not necessarily registration in all regions.
Certain applications may require additional third-party intellectual property rights.
Yeasen is dedicated to ethical science, believing our research should address critical questions while ensuring safety and ethical standards.